2014
Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW. Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. PLOS ONE 2014, 9: e96389. PMID: 24816692, PMCID: PMC4015982, DOI: 10.1371/journal.pone.0096389.Peer-Reviewed Original ResearchConceptsShort-course regimensTB incidenceTreatment completionTreatment successFirst-line treatment regimensFour-month regimenFour-month regimensLower treatment completionProportion of patientsPopulation-level incidenceSix-month therapyGlobal tuberculosis incidenceDynamic transmission modelPopulation-level transmissionCourse regimensTB diseaseTB patientsNew regimensRelapse rateTB mortalityTB transmissionTreatment regimensTuberculosis incidenceClinical trialsRegimens
2013
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
Owens JP, Fofana MO, Dowdy DW. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 590-596. PMID: 23575322, PMCID: PMC3844288, DOI: 10.5588/ijtld.12.0776.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsFirst-line treatmentStandard treatmentTotal disability-adjusted life yearsFailure/relapseShort-course regimensFirst-line regimensFirst-line drugsHigher drug costsHealth care perspectiveDrug pricesTB patientsActive tuberculosisNovel regimensPatient cohortDrug costsEqual efficacyRegimensLife yearsCare perspectiveTuberculosisRelapsePatientsTreatmentShort duration